What is Julie Kim's background at Takeda?

Kim joined Takeda through the company's 2019 acquisition of Shire, an Ireland-based pharmaceutical firm, and is now transitioning from that division to lead the entire organization.

What are Kim's stated priorities as CEO?

Kim committed to inheriting Takeda's values, generating innovative pharmaceuticals, and focusing on talented people and innovation while advancing AI utilization and leaner management practices.

Top Companies' AI MovesTop Companies AIJun 25, 2026Jun 26, 2026, 06:30 JST1 min read

Julie Kim named Takeda CEO, prioritizes AI drug innovation

Send on LINE

Key takeaway

Takeda Pharmaceutical has appointed Julie Kim, an executive from the Shire division acquired in 2019, as its new Chief Executive Officer.
Kim plans to continue structural reforms and deploy artificial intelligence to achieve leaner operations while accelerating innovative drug development, marking a shift toward efficiency-driven pharmaceutical research for Japan's largest drugmaker.

3 Key Points

What happened
Julie Kim, who joined Takeda through its 2019 acquisition of Ireland-based Shire, has been named the company's new Chief Executive Officer. At a press conference the day after taking office, Kim stated her commitment to inheriting Takeda's values while driving innovative drug development, emphasizing focus on talented people and innovation.
Why it matters
Kim is continuing a structural reform strategy and advancing AI utilization to achieve leaner management. For Takeda's stakeholders—investors, employees, and patients—this signals a shift toward efficiency-driven innovation in drug development, a capital-intensive business where both cost control and breakthrough research are critical.
What to watch
Kim's stated priorities are to deliver innovative pharmaceuticals while strengthening the company's human capital and innovation focus. The integration of AI tools into drug development processes will be a key metric of whether the strategy translates into faster time-to-market and cost savings.

Ask the AI about this article →

Summaries like this, in your inbox every morning.

Get news like this every morning — free

FAQ

What is Julie Kim's background at Takeda?: Kim joined Takeda through the company's 2019 acquisition of Shire, an Ireland-based pharmaceutical firm, and is now transitioning from that division to lead the entire organization.
What are Kim's stated priorities as CEO?: Kim committed to inheriting Takeda's values, generating innovative pharmaceuticals, and focusing on talented people and innovation while advancing AI utilization and leaner management practices.